Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 4, Pages 731-736
Publisher
Oxford University Press (OUP)
Online
2015-01-28
DOI
10.1093/annonc/mdv005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- O-0011 * FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY
- (2014) K. Newhall et al. ANNALS OF ONCOLOGY
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
- (2014) F. Ciardiello et al. ANNALS OF ONCOLOGY
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
- (2014) L. De Mattos-Arruda et al. ANNALS OF ONCOLOGY
- Characterization of rare transformingKRASmutations in sporadic colorectal cancer
- (2014) Joanna HM Tong et al. CANCER BIOLOGY & THERAPY
- TGF and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
- (2014) S. Hobor et al. CLINICAL CANCER RESEARCH
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
- (2013) D. Tougeron et al. ANNALS OF ONCOLOGY
- The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
- (2013) Claudia Esposito et al. CANCER BIOLOGY & THERAPY
- Increased TGF- as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- (2013) T. Troiani et al. CLINICAL CANCER RESEARCH
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- (2012) D. Santini et al. ANNALS OF ONCOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- MR Volumetric Measurement of Low Rectal Cancer Helps Predict Tumor Response and Outcome after Combined Chemotherapy and Radiation Therapy
- (2012) Stephanie Nougaret et al. RADIOLOGY
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started